Skip to main content
. 2021 Jul 16;65(8):e00552-21. doi: 10.1128/AAC.00552-21

TABLE 8.

Efficacy of CTB/VNRX-5236 and CTB/VNRX-7145 against K. pneumoniae UNT-023 expressing KPC, TEM-1, and SHV-11a

Antimicrobial agent MIC (μg/ml) Route of administration ED50 (mg/kg) 95% confidence limit
CTB alone 64 PO >128 NA
CTB/VNRX-7145 ND PO/PO 12.9 9.8–17.2
CTB/VNRX-5236 0.25 SC/SC 13.5 9.1–22.8
a

 NA, not applicable due to lack of protection; ND, not determined, as VNRX-7145 (VNRX-5236 etzadroxil) has no demonstrable BLI activity; PO, per os (by mouth); SC, subcutaneous; ED50, 50% effective dose.